Abstract:Objective: The CAPTURE study found that the prevalence of CVD in adults with T2D is approximately 1 in 3. This post hoc analysis determined the association between CVD risk factors (RF) and CVD.Methods: CAPTURE was a cross-sectional, non-interventional study in people with T2D across 13 countries. Participant data were collected during a single routine clinical visit in a primary or specialist settings between Dec 1, 2018 and Sep, 2019. A multivariable logistic regression model was used to calculate prevalence odds ratios (PORs).Results: Data were from 6369 participants with the information available for all included variables from the total CAPTURE population (N=9823). Age and CKD (assessed by eGFR) were positively associated with CVD status (both p<0.0001). Other RF with high CVD PORs were: diagnosed hypertension (1.87), smoking (1.53), male sex (1.29), diabetes-related variables, HbA1c (1.07) and diabetes duration (1.01). Serum LDL-C and HDL-C had a negative association with CVD (both p <0.0001, Table).Conclusion: The high CVD prevalence in the CAPTURE study is associated with demographics, classic CVD RF and diabetes-related variables, especially CKD. A negative association with LDL-C reflect confounding through indication for the use of lipid-lowering agents. These data support the use of antidiabetes drugs with proven CV benefit on several CV RFs in people with T2D and CVD.View largeDownload slideView largeDownload slide DisclosureA. M. Alguwaihes: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Novo Nordisk, Sanofi, Research Support; Self; AstraZeneca, Novo Nordisk, Speaker’s Bureau; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Novo Nordisk, Sanofi. C. Lengyel: Other Relationship; Self; AstraZeneca, Berlin-Chemie AG, Boehringer Ingelheim International GmbH, EGIS, KRKA, Lilly Hungária Kft, MSD Corporation, Novartis AG, Novo Nordisk, Pfizer Inc., Richter Gedeon, Sandoz International GmbH, Sanofi-Aventis, Servier Laboratories, Teva Pharmaceutical Industries Ltd., Wörwag Pharma. O. Mosenzon: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., BOL Pharma, Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk, Sanofi, Research Support; Self; AstraZeneca, Novo Nordisk, Speaker’s Bureau; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk, Sanofi. G. T. Russo: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Merck Sharp & Dohme Corp., Novartis AG, Novo Nordisk, Sanofi, Speaker’s Bureau; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Merck Sharp & Dohme Corp., Novartis AG, Novo Nordisk, Sanofi. S. Shirabe: Other Relationship; Self; Merck Sharp & Dohme Corp., Novo Nordisk, Sumitomo Dainippon Pharma Co., Ltd. K. Urbancova: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Novo Nordisk, Consultant; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, MSD Corporation, Novo Nordisk, Speaker’s Bureau; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Merck & Co., Inc., MSD Corporation, Novo Nordisk, Zentiva. S. Vencio: Advisory Panel; Self; Boehringer Ingelheim International GmbH, Novartis AG, Novo Nordisk, Other Relationship; Self; Boehringer Ingelheim International GmbH, Novartis AG, Novo Nordisk, Speaker’s Bureau; Self; Boehringer Ingelheim International GmbH, Novartis AG, Novo Nordisk. G. Yadav: Employee; Self; Novo Nordisk. J. A. Leon: Advisory Panel; Self; AstraZeneca, Merck Sharp & Dohme Corp., Novartis AG, Novo Nordisk, Research Support; Self; Amgen Inc., AstraZeneca, Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., Novartis AG, Novo Nordisk, Sanofi, Takeda Pharmaceutical Co., Speaker’s Bureau; Self; AstraZeneca, Merck & Co., Inc., Merck Sharp & Dohme Corp., Novo Nordisk. F. Bayram: Advisory Panel; Self; Novo Nordisk A/S, Sanofi Genzyme, Consultant; Self; Lilly Diabetes, Novo Nordisk, Pfizer Inc. P. Darmon: Advisory Panel; Self; Abbott, AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, MSD Corporation, Mundipharma International, Novartis AG, Novo Nordisk, Sanofi, Research Support; Self; Boehringer Ingelheim International GmbH, Eli Lilly and Company, Novo Nordisk, Speaker’s Bureau; Self; Abbott, AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, MSD Corporation, Mundipharma International, Novartis AG, Novo Nordisk, Sanofi. T. Davis: Advisory Panel; Self; Merck Sharp & Dohme Corp. Speaker's Bureau; Self; Novo Nordisk. Other Relationship; Self; Novo Nordisk. G. Dieuzeide: Advisory Panel; Self; AstraZeneca, Novo Nordisk, Roche Diagnostic USA, Sanofi. Speaker's Bureau; Self; AstraZeneca, Novo Nordisk, Roche Diagnostic USA, Sanofi. K.T. Eriksen: Employee; Self; Novo Nordisk. T. Hong: Speaker's Bureau; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Merck Sharp & Dohme Corp., Novo Nordisk, Sanofi. T.J. Jensen: Employee; Self; Novo Nordisk. C. Lengyel: Other Relationship; Self; AstraZeneca, Berlin-Chemie AG, Boehringer Ingelheim International GmbH, EGIS, KRKA, Lilly Hungária Kft, MSD Corporation, Novartis AG, Novo Nordisk, Pfizer Inc., Richter Gedeon, Sandoz International GmbH, Sanofi-Aventis, Servier Laboratories, Teva Pharmaceutical Industries Ltd., Wörwag Pharma. O. Mosenzon: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., BOL Pharma, Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk, Sanofi. Research Support; Self; AstraZeneca, Novo Nordisk. Speaker's Bureau; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk, Sanofi. G.T. Russo: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Merck Sharp & Dohme Corp., Novartis AG, Novo Nordisk, Sanofi. Speaker's Bureau; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Merck Sharp & Dohme Corp., Novartis AG, Novo Nordisk, Sanofi. S. Shirabe: Other Relationship; Self; Merck Sharp & Dohme Corp., Novo Nordisk, Sumitomo Dainippon Pharma Co., Ltd. K. Urbancova: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Novo Nordisk. Consultant; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, MSD Corporation, Novo Nordisk. Speaker's Bureau; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Merck & Co., Inc., MSD Corporation, Novo Nordisk, Zentiva. S. Vencio: Advisory Panel; Self; Boehringer Ingelheim International GmbH, Novartis AG, Novo Nordisk. Speaker's Bureau; Self; Boehringer Ingelheim International GmbH, Novartis AG, Novo Nordisk. Other Relationship; Self; Boehringer Ingelheim International GmbH, Novartis AG, Novo Nordisk. G. Yadav: Employee; Self; Novo Nordisk.

Individualized HbA1c Targets in People with Type 2 Diabetes Initiating Second-Line Therapy-The Global DISCOVER Study

Temporal Trends in the Use of Sodium-Glucose Cotransporter-2 Inhibitors: the Global DISCOVER Study

What are the factors associated with long-term glycaemic control in patients with type 2 diabetes and elevated glycated haemoglobin (7.0%) at initiation of second-line therapy? Results from the DISCOVER study

Health-related quality of life in patients with type 2 diabetes initiating a second-line glucose-lowering therapy: The DISCOVER study

Type 2 diabetes treatment and outcomes worldwide: A short review of the DISCOVER study programme

990-P: Use of Glucose-Lowering Agents According to Cardiovascular Risk Factors in People with T2D and with or Without CVD in the CAPTURE Study

Socioeconomic factors associated with hypoglycaemia in patients starting second-line glucose-lowering therapy: The DISCOVER study

GOAL study: clinical and non-clinical predictive factors for achieving glycemic control in people with type 2 diabetes in real clinical practice

677-P: Remission of Type 2 Diabetes following Intensive Treatment with Insulin Glargine, Lixisenatide, Metformin, and Lifestyle Approaches: Results of a Multicenter Randomized Controlled Trial

Individualizing treatment targets for elderly patients with type 2 diabetes: factors influencing clinical decision making in the 24-week, randomized INTERVAL study

436-P: Stringent Glycemic Control and Long-Term Macrovascular Outcomes in People with Type 2 Diabetes in China—A Retrospective Study

785-P: Comparative Effectiveness of Second-Line Glucose-Lowering Medications—Emulation of a Target Trial Using Real-World Data

Abstract 261: Global Patterns of Comprehensive Cardiovascular Risk Factor Control in Patients with Type 2 Diabetes Mellitus: Insights from the Global DISCOVER Registry

1901-LB: Safety and Glycemic Outcomes Using the MiniMed 780G System with a Disposable All-in-One Sensor with Transmitter

Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DM

Protocol for an observational cohort study investigating personalised medicine for intensification of treatment in people with type 2 diabetes mellitus: the PERMIT study

274-OR: Effect of Testosterone Treatment on Type 2 Diabetes Incidence in High-Risk Men Enrolled in a Lifestyle Program: A Two-Year Randomized Placebo-Controlled Trial

1051-P: Inside CKD: Modeling the Future Global Burden of Chronic Kidney Disease in Patients with Type 2 Diabetes

974-P: Associations Between Patient Characteristics and Cardiovascular Disease: A Post-hoc Analysis from the CAPTURE Study

92-OR: Persistence of Impaired Awareness of Hypoglycemia, Severe Hypoglycemic Events, and Suboptimal Glycemic Control Despite Advanced Diabetes Technologies

GBT021601, a Next Generation HbS Polymerization Inhibitor: Results of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Adults Living with Sickle Cell Disease and Healthy Volunteers